Real-world evidence: Flatiron Electronic Health Record Database study of EGFR TKIs

Erlotinib was the most widely prescribed first-line therapy for EGFR Mut+ NSCLC in this study, with similar efficacy observed for erlotinib- and afatinib-treated patients. The efficacy of EGFR TKIs observed in clinical studies was reflected in the real world setting.1

Study overview1

  •  This retrospective cohort analysis examined the management patterns and outcomes of patients with EGFR Mut+ NSCLC in a real-world setting, using data from the US Flatiron Electronic Health Record database.

Key Results

EGFR mutation test rate1

Rates of EGFR mutation testing increased from 2011until 2016.

Usage frequency of different first-line therapies1

Erlotinib was the most widely prescribed therapy for first-line treatment of EGFR Mut+ NSCLC.

Time to next treatment1

Patients receiving erlotinib or afatinib had longer time to next treatment than those receiving non-EGFR TKI therapy.

*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab TTNT = time to next treatment

Overall survival1

There were no significant differences in overall survival by treatment group.

*Defined as all non-EGFR TKI treatments including chemotherapy and bevacizumab